Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tests MS drug ofatumumab in greek clinics

NCT ID NCT06486779

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 160 people with relapsing multiple sclerosis in Greece who are already taking ofatumumab (Kesimpta®) as part of their routine care. Researchers will track how many patients have no signs of disease activity—like relapses, new brain lesions, or worsening disability—over time. The goal is to see if the drug works as well in real-world settings as it did in earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ofatumumab (Kesimpta®)

What this could lead to

If successful, this study could confirm that ofatumumab works as well in everyday clinics as it does in controlled trials, supporting its use for relapsing MS.

What could go wrong

This is an observational study, not a controlled experiment, so results may be influenced by patient selection or other factors. It is also limited to Greece, so findings may not apply everywhere.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS (RMS)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Athens, Attica, 15562, Greece

  • Novartis Investigative Site

    RECRUITING

    Athens, GR, 115 26, Greece

  • Novartis Investigative Site

    RECRUITING

    Alexandroupoli, 681 00, Greece

  • Novartis Investigative Site

    RECRUITING

    Athens, 115 21, Greece

  • Novartis Investigative Site

    RECRUITING

    Athens, 115 25, Greece

  • Novartis Investigative Site

    RECRUITING

    Athens, 115 27, Greece

  • Novartis Investigative Site

    WITHDRAWN

    Athens, 115 28, Greece

  • Novartis Investigative Site

    RECRUITING

    Athens, 145 61, Greece

  • Novartis Investigative Site

    RECRUITING

    Chaïdári, 124 62, Greece

  • Novartis Investigative Site

    RECRUITING

    Crete Heraklion, 714 09, Greece

  • Novartis Investigative Site

    RECRUITING

    Ioannina, 455 00, Greece

  • Novartis Investigative Site

    RECRUITING

    Larissa, 411 10, Greece

  • Novartis Investigative Site

    RECRUITING

    Pátrai, 265 04, Greece

  • Novartis Investigative Site

    RECRUITING

    Thessaloniki, 53246, Greece

  • Novartis Investigative Site

    RECRUITING

    Thessaloniki, 54636, Greece